TG Therapeutics, Inc. (TGTX) stock
TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$66.12+3.41 (+5.44%)
Close on Nov 18, 2026Market cap $10.12BP/E 24.1Yield –
TG Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
TG Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $17.88M. For fiscal 2025 it was -$24.77M. The highest annual figure on record is -$86.58K in fiscal 2011.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$24.77M | – |
| FY2024 | Dec 31, 2024 | -$40.52M | – |
| FY2023 | Dec 31, 2023 | -$31.41M | – |
| FY2022 | Dec 31, 2022 | -$176.17M | – |
| FY2021 | Dec 31, 2021 | -$295.63M | – |
| FY2020 | Dec 31, 2020 | -$214.51M | – |
| FY2019 | Dec 31, 2019 | -$132.81M | – |
| FY2018 | Dec 31, 2018 | -$128.93M | – |
| FY2017 | Dec 31, 2017 | -$93.76M | – |
| FY2016 | Dec 31, 2016 | -$61.59M | – |
| FY2015 | Dec 31, 2015 | -$44.69M | – |
| FY2014 | Dec 31, 2014 | -$35.06M | – |
| FY2013 | Dec 31, 2013 | -$10.74M | – |
| FY2012 | Dec 31, 2012 | -$5.19M | – |
| FY2011 | Dec 31, 2011 | -$86.58K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $39.26M | +428.0% |
| Q1 FY2026 | Mar 31, 2026 | -$17.89M | – |
| Q4 FY2025 | Dec 31, 2025 | $19.66M | – |
| Q3 FY2025 | Sep 30, 2025 | -$23.15M | – |
| Q2 FY2025 | Jun 30, 2025 | $7.44M | +34.3% |
| Q1 FY2025 | Mar 31, 2025 | -$28.72M | – |
| Q4 FY2024 | Dec 31, 2024 | -$25.64M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.21M | -114.6% |
| Q2 FY2024 | Jun 30, 2024 | $5.54M | – |
| Q1 FY2024 | Mar 31, 2024 | -$8.21M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.21M | – |
| Q3 FY2023 | Sep 30, 2023 | $83.70M | – |
| Q2 FY2023 | Jun 30, 2023 | -$42.01M | – |
| Q1 FY2023 | Mar 31, 2023 | -$59.90M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.87M | – |
| Q3 FY2022 | Sep 30, 2022 | -$34.50M | – |
| Q2 FY2022 | Jun 30, 2022 | -$49.12M | – |
| Q1 FY2022 | Mar 31, 2022 | -$68.69M | – |
| Q4 FY2021 | Dec 31, 2021 | -$86.91M | – |
| Q3 FY2021 | Sep 30, 2021 | -$67.20M | – |
| Q2 FY2021 | Jun 30, 2021 | -$60.17M | – |
| Q1 FY2021 | Mar 31, 2021 | -$81.36M | – |
| Q4 FY2020 | Dec 31, 2020 | -$52.03M | – |
| Q3 FY2020 | Sep 30, 2020 | -$56.53M | – |
| Q2 FY2020 | Jun 30, 2020 | -$43.83M | – |
| Q1 FY2020 | Mar 31, 2020 | -$62.12M | – |
| Q4 FY2019 | Dec 31, 2019 | -$30.39M | – |
| Q3 FY2019 | Sep 30, 2019 | -$33.20M | – |
| Q2 FY2019 | Jun 30, 2019 | -$35.86M | – |
| Q1 FY2019 | Mar 31, 2019 | -$33.35M | – |
| Q4 FY2018 | Dec 31, 2018 | -$33.69M | – |
| Q3 FY2018 | Sep 30, 2018 | -$33.01M | – |
| Q2 FY2018 | Jun 30, 2018 | -$34.18M | – |
| Q1 FY2018 | Mar 31, 2018 | -$28.04M | – |
| Q4 FY2017 | Dec 31, 2017 | -$21.86M | – |
| Q3 FY2017 | Sep 30, 2017 | -$22.78M | – |
| Q2 FY2017 | Jun 30, 2017 | -$26.83M | – |
| Q1 FY2017 | Mar 31, 2017 | -$22.30M | – |
| Q4 FY2016 | Dec 31, 2016 | -$17.02M | – |
| Q3 FY2016 | Sep 30, 2016 | -$15.04M | – |
See a number that looks wrong?